Canada markets closed

Cronos Group Inc. (CRON.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
10.39-0.21 (-1.98%)
At close: 4:00PM EDT
Full screen
Previous Close10.60
Open10.64
Bid10.39 x 0
Ask10.40 x 0
Day's Range10.34 - 10.69
52 Week Range6.55 - 20.08
Volume816,139
Avg. Volume471,839
Market Cap3.862B
Beta (5Y Monthly)1.83
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • Cronos Group Announces Strategic Investment in PharmaCann, a Leading U.S. Cannabis Company
    GlobeNewswire

    Cronos Group Announces Strategic Investment in PharmaCann, a Leading U.S. Cannabis Company

    Investment is Expected to Position Cronos Group to Benefit from Rapid Growth in the U.S. Cannabis Market PharmaCann is Well Positioned in Limited License States Across the Midwest and Northeast TORONTO and CHICAGO, June 14, 2021 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group”) and PharmaCann Inc. (“PharmaCann”), one of the largest vertically integrated cannabis companies in the United States (“U.S.”), today announced that they have entered into an agreement under

  • Four Cannabis Stocks for the Summer of 2021
    GlobeNewswire

    Four Cannabis Stocks for the Summer of 2021

    Cannabis stocks have resumed their upward trend. Here are four stocks to consider.ATLANTA, June 10, 2021 (GLOBE NEWSWIRE) -- Cannabis stocks have staged a rousing return in recent weeks after a quiet first half of 2021. Sales are on the rise this year as revenue and profits for many cannabis companies have increased significantly. During the global COVID-19 pandemic medical marijuana was deemed "essential,” which definitely had an impact on increased sales. U.S. legal cannabis sales grew 46% yea

  • Cronos Group and Ginkgo Bioworks Amend Agreement to Accelerate Commercialization of Cultured Cannabinoids and Cronos Group Begins Commercial Production of CBG
    GlobeNewswire

    Cronos Group and Ginkgo Bioworks Amend Agreement to Accelerate Commercialization of Cultured Cannabinoids and Cronos Group Begins Commercial Production of CBG

    BOSTON and TORONTO, June 04, 2021 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group”), an innovative global cannabinoid company, and Ginkgo Bioworks, Inc. (“Ginkgo”), which is building the leading horizontal platform for cell programming, today announced an amended collaboration and license agreement (the “Amended Agreement”) that will enable the companies to accelerate the commercialization of cultured cannabinoids at scale. The Amended Agreement with Ginkgo will e